Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
HALO Analyst Ratings
Moderate Buy
5 Buy
4 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HALO Stock 12 Month Forecast
Average Price Target
$64.80
▲(11.26%Upside)
| Highest Price Target$79.00 | Average Price Target$64.80 | Lowest Price Target$47.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$64
Buy
9.89%
Upside
Reiterated
07/09/25
Halozyme's strong financial performance and impressive earnings call, highlighting significant growth and increased guidance, are major positive factors. The technical indicators suggest moderate momentum, while the valuation indicates potential undervaluation. The high leverage risk is notable but manageable.
Morgan Stanley
$62
Hold
6.46%
Upside
Reiterated
07/21/25
Hold Rating for Halozyme Amid CMS Pricing Uncertainty and Regulatory ConcernsWe believe investors should look for details regarding: (1) potential impact of regulatory updates on Halozyme future revenues; (2) any updates to FY25 financial guidances; and (3) guidance on capital management and business development efforts. We are uncertain how CMS draft pricing guidance might affect long-term HALO revenues. Recall CMS issued draft guidance on May 12 that could impact drug pricing negotiations for fixed combination drugs, especially when the 2nd active ingredient (e.g., hyaluronidase) affects bioavailability of the active drug moiety addressing the underlying disease state (see the draft guidance here).
J.P. Morgan
$58→$60
Hold
3.02%
Upside
Reiterated
07/16/25
Goldman Sachs
$55
Hold
-5.56%
Downside
Initiated
07/10/25
TD Cowen
$79
Buy
35.65%
Upside
Reiterated
06/10/25
Wells Fargo
$65
Hold
11.61%
Upside
Reiterated
06/02/25
We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.
H.C. Wainwright
$72
Buy
23.63%
Upside
Reiterated
05/29/25
Leerink Partners
$63→$47
Sell
-19.30%
Downside
Downgraded
05/15/25
Evercore ISI
$55
Buy
-5.56%
Downside
Reiterated
05/15/25
Benchmark Co.
$75
Buy
28.78%
Upside
Reiterated
05/14/25
Citizens JMP
$78
Buy
33.93%
Upside
Reiterated
05/14/25
Piper Sandler
$53
Hold
-9.00%
Downside
Reiterated
03/06/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$64
Buy
9.89%
Upside
Reiterated
07/09/25
Halozyme's strong financial performance and impressive earnings call, highlighting significant growth and increased guidance, are major positive factors. The technical indicators suggest moderate momentum, while the valuation indicates potential undervaluation. The high leverage risk is notable but manageable.
Morgan Stanley
$62
Hold
6.46%
Upside
Reiterated
07/21/25
Hold Rating for Halozyme Amid CMS Pricing Uncertainty and Regulatory ConcernsWe believe investors should look for details regarding: (1) potential impact of regulatory updates on Halozyme future revenues; (2) any updates to FY25 financial guidances; and (3) guidance on capital management and business development efforts. We are uncertain how CMS draft pricing guidance might affect long-term HALO revenues. Recall CMS issued draft guidance on May 12 that could impact drug pricing negotiations for fixed combination drugs, especially when the 2nd active ingredient (e.g., hyaluronidase) affects bioavailability of the active drug moiety addressing the underlying disease state (see the draft guidance here).
J.P. Morgan
$58→$60
Hold
3.02%
Upside
Reiterated
07/16/25
Goldman Sachs
$55
Hold
-5.56%
Downside
Initiated
07/10/25
TD Cowen
$79
Buy
35.65%
Upside
Reiterated
06/10/25
Wells Fargo
$65
Hold
11.61%
Upside
Reiterated
06/02/25
We rate HALO Equal Weight as we believe the value of the company's current partnerships and anticipated new launches are in the name.
H.C. Wainwright
$72
Buy
23.63%
Upside
Reiterated
05/29/25
Leerink Partners
$63→$47
Sell
-19.30%
Downside
Downgraded
05/15/25
Evercore ISI
$55
Buy
-5.56%
Downside
Reiterated
05/15/25
Benchmark Co.
$75
Buy
28.78%
Upside
Reiterated
05/14/25
Citizens JMP
$78
Buy
33.93%
Upside
Reiterated
05/14/25
Piper Sandler
$53
Hold
-9.00%
Downside
Reiterated
03/06/25
Best Analysts Covering Halozyme
1 Month
xxx
Success Rate
16/27 ratings generated profit
Average Return
+2.68%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +2.68% per trade.
3 Months
xxx
Success Rate
9/16 ratings generated profit
Average Return
+5.86%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.25% of your transactions generating a profit, with an average return of +5.86% per trade.
1 Year
Success Rate
17/22 ratings generated profit
Average Return
+21.17%
reiterated a buy rating 2 months ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +21.17% per trade.
2 Years
xxx
Success Rate
14/16 ratings generated profit
Average Return
+31.03%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 87.50% of your transactions generating a profit, with an average return of +31.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HALO Analyst Recommendation Trends
Rating
Mar 25
Apr 25
May 25
Jun 25
Jul 25
Strong Buy
0
0
3
3
3
Buy
15
12
12
11
12
Hold
7
6
6
6
7
Sell
0
0
1
1
1
Strong Sell
0
0
0
0
0
total
22
18
22
21
23
Each month's total comprises the sum of three months' worth of ratings.
HALO Financial Forecast
HALO Stock Forecast FAQ
What is HALO’s average 12-month price target, according to analysts?
Based on analyst ratings, Halozyme Therapeutics’s 12-month average price target is 64.80.
What is HALO’s upside potential, based on the analysts’ average price target?
Halozyme Therapeutics has 11.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HALO a Buy, Sell or Hold?
Halozyme Therapeutics has a consensus rating of Moderate Buy which is based on 5 buy ratings, 4 hold ratings and 1 sell ratings.
What is Halozyme Therapeutics’s price target?
The average price target for Halozyme Therapeutics is 64.80. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $79.00 ,the lowest forecast is $47.00. The average price target represents 11.26% Increase from the current price of $58.24.
The highest analyst price target is $79.00 ,the lowest forecast is $47.00. The average price target represents 11.26% Increase from the current price of $58.24.
What do analysts say about Halozyme Therapeutics?
Halozyme Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.
How can I buy shares of HALO?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.